Insecticides India’s record carries a clean audit history and a promoter group that has put personal guarantees behind company borrowings. Three things deserve attention: a ₹78 crore DGFT show-cause notice has sat unresolved since 2019 with no provision, operating cash flow has persistently trailed reported profit, and revenue recognition is a recurring Key Audit Matter while receivables have stretched to 83 days.
Key findings
- A ₹78 crore DGFT notice remains stayed since 2019 with no provision
Major- The Additional Director of Foreign Trade, Ahmedabad issued a show-cause notice on 28 November 2019 demanding repayment of ₹7,828.87 lacs plus 15% interest for Terminal Excise Duty refunds across FY2014-15 to FY2016-17. The Gujarat High Court granted interim relief and stayed proceedings, and no provision has been recorded. Meanwhile, disputed income-tax demands shrank from ₹9,211 lacs across six assessment years in FY2022-23 to ₹1.68 crore across four assessment years in FY2025-26, and a new ₹52 crore Letter of Comfort was issued to ICICI Bank for subsidiary Kaeros Research on 27 February 2025. - Operating cash flow has persistently lagged profit, while capital allocation favoured shareholder returns over debt reduction
Minor- Cumulative CFO of ₹955 crore covered only 0.58x of cumulative EBITDA of ₹1,657 crore over the ten years to FY26. In FY26, CFO was ₹100 crore against PAT of ₹139 crore, and consolidated finance cost more than doubled from ₹6.86 crore to ₹16.87 crore, which management attributed to higher inventory and investment of ₹94 crore in new products from internal accruals. The company completed a ₹50 crore buyback in FY25 and paid dividends of ₹2 per share in FY26, while short-term borrowings constituted 82% of total borrowings as of FY26. - Revenue recognition is a recurring Key Audit Matter, and receivables have lengthened to 83 days
Minor- The independent auditor has identified revenue recognition as a Key Audit Matter in every annual report from FY2020-21 through FY2025-26, citing judgement in rebates, discounts, and sales returns. Standalone trade receivables rose from ₹385.68 crore to ₹489.50 crore during FY26, and receivable days increased from 55 in FY24 to 70 in FY25 and 83 in FY26. Management states that at the end of each season the company takes back all unsold inventory from the channel for reformulation, with no write-offs taken in the market. - The group has expanded from a single joint venture to multiple subsidiaries, including a related-party acquisition with outsized margins
Minor- From FY2019 through FY2022 the group had no subsidiaries; by FY2026 it had incorporated IIL Biologicals Limited, dissolved IIL Overseas DMCC without it ever conducting operations, and acquired 100% of Kaeros Research from promoter-family members for 6.24 crore under the pooling-of-interest method. In its second year under the group, Kaeros generated a PAT margin above ₹5 crores, and management states it will operate a parallel distribution network with no shared distributors. - Clean audit opinions across all years, with one historical employee fraud and a recurring audit-trail gap
Minor- The statutory auditors issued an unqualified opinion on standalone financial statements for every year from FY19 through FY26. In FY21, the auditors included an Emphasis of Matter, a special call-out in the audit report, disclosing a fraud of ₹9.7 crore by two employees in collusion with dealers, which was fully provided as an exceptional item. The audit-trail feature at the database level was not enabled for the full year in any period since the requirement became applicable: in FY26 it was enabled except at certain critical database tables. - Regulator actions are limited to a minor procedural fine and a SEBI exemption for promoter succession transfers
Clean- BSE and NSE each levied a fine of ₹10,000 plus GST because the record date for a buyback fell within 30 days of the previous record date for an interim dividend; the company paid the penalty. SEBI granted an exemption order on 2 December 2025 to promoters for inter-se transfer of equity shares by gift to private family trusts for succession planning, exempting them from open offer obligations. The company disclosed a one-time exceptional expense of ₹970.15 lacs in FY2021 for the employee fraud, and an FIR was filed on 4 July 2020 at P.S. Janjgir, Chhattisgarh.
What to watch
- DGFT show-cause notice. Outcome of the writ petition before the Gujarat High Court against the ₹7,828.87 lacs demand dated 28 November 2019; interim stay remains in effect as of the FY2025-26 reporting period.
- Sanskar Aggarwal appointment and ESPS 2026. Voting at the 29th AGM scheduled 12 August 2026 on the special resolutions to appoint Sanskar Aggarwal as Whole-time Director and approve the ESPS 2026.
- Letter of Comfort invocation. Any invocation of the ₹52 crore Letter of Comfort issued to ICICI Bank on 27 February 2025 for Kaeros Research.
- Audit-trail gap. Resolution of the recurring gap at the database level, to be reported in the FY27 auditor’s report.
- Trade receivables. Standalone trade receivables as at 31 March 2027 and the FY2026-27 trade receivables turnover ratio, to be disclosed in the next AGM notice.
Bottom line: This is a disclosed and consistently audited record with a promoter group that stands behind company debt through personal guarantees. The risk sits in three places: a seven-year-old DGFT notice that remains unresolved without provision, a cash conversion cycle that has never fully caught up with reported earnings, and a revenue-recognition judgement that the auditor flags every year while receivables keep stretching. Watch the Gujarat High Court outcome, the AGM vote on the third-generation appointment, and whether the audit-trail gap finally closes in FY27.